RRM2/GCH1 signaling decreased cisplatin sensitivity in cervical cancer by modulating the ferroptosis process.

Abstract

BACKGROUND: Cisplatin-based chemotherapy serves as a fundamental approach in the treatment of cervical cancer; however, its effectiveness is often hindered by the development of drug resistance, which presents a significant obstacle in clinical practice. METHODS: studies were carried out to explore the influence of Ribonucleotide reductase M2 (RRM2) on the effectiveness of cisplatin chemotherapy. RESULTS: . Finally, our experiments established a positive association between RRM2 and the classical ferroptosis inhibition factor GTP cyclohydrolase 1 (GCH1) by immunofluorescence and immunoblotting. CONCLUSION: RRM2 plays roles in the evaluation and outcome prediction of cervical cancer, potentially impacting cisplatin sensitivity through regulation of ferroptosis. This investigation provides novel insights into the tumorigenic functions of RRM2, highlighting its potential use as a prognostic biomarker in cervical carcinoma.